Sativex® (GW Pharmaceuticals) is an oromucosal whole cannabis-based spray combining a CB1 partial agonist (THC) with a cannabinoid system modulator (CBD), minor cannabinoids and terpenoids plus ethanol and propylene glycol excipients and peppermint flavoring (McPartland and Russo 2001; Russo and Guy 2006). It was approved by Health Canada in June 2005 for prescription for central neuropathic pain in multiple sclerosis, and in August 2007, it was additionally approved for treatment of cancer pain unresponsive to optimized opioid therapy. Sativex is a highly standardized pharmaceutical product derived from two Cannabis sativa chemovars following Good Agricultural Practice (GAP) (de Meijer 2004), yielding Tetranabinex® (predominantly-THC extract) and Nabidiolex® (predominantly-CBD extract) in a 1:1 ratio. Each 100 μL pump-action oromucosal Sativex spray actuation provides 2.7 mg of THC and 2.5 mg of CBD. Pharmacokinetic data are available, and indicate plasma half lives of 85 minutes for THC, 130 minutes for 11-hydroxy-THC and 100 minutes for CBD (Guy and Robson 2003). Sativex effects commence in 15–40 minutes, an interval that permits symptomatic dose titration. A very favorable adverse event profile has been observed in over 2500 patient years of exposure in over 2000 experimental subjects. Patients most often ascertain an individual stable dosage within 7–10 days that provides therapeutic relief without unwanted psychotropic effects (often in the range of 8–10 sprays per day). In all RCTs, Sativex was adjunctively added to optimal drug regimens in subjects with intractable symptoms, those often termed “untreatable.” Sativex is also available by named patient prescription in the UK and the Catalonia region of Spain. An Investigational New Drug (IND) application to study Sativex in advanced clinical trials in the USA was approved by the FDA in January 2006 in patients with intractable cancer pain.
The Hemp Industries Association (HIA) is a non-profit trade association representing more than one-thousand (1,000) supporters, farmers and business members serving the hemp industries since 1994. The hemp industries are primed to once again become a major global economic force as a result of new applications and opportunities that are in demand. Hemp is a sustainable choice for industrial products, textiles, and also offer exceptional ingredients and components for nutrition and wellness products. Hemp is one of our planet's most important natural resources, and we advocate for the whole plant.
The first time I came across CBD was when I was visiting my brother in San Antonio, Texas 2 years back. The one day I had some serious back pain, My brother's neighbour suggested that I should try CBD oil for my pain as it helps his mom with her cancer pain, and directed me to SABotanicals, a local CBD store in San Antonio where I bought a 2000mg CBD oil.In the beginning, I was a sceptic, but it worked so well that I ordered three more bottles to last me for a few months. I must say that also felt relaxed but could do my work with no issues as it didn't make me high.To date, I'm still using CBD oil for my paid and came off pain medications completely.God gave us something great!
Breeding for low THC cultivars in Europe has been reviewed by Bócsa (1998), Bócsa and Karus (1998), and Virovets (1996). Some researchers have claimed to have produced essentially THC-free strains, although at present no commercial cultivar seems to be 100% free of THC. THC content has proven to be more easily reduced in monoecious than in dioecious varieties. It should be possible to select THC-free strains, and there has been speculation that genetic engineering could be helpful in this regard. As a strategic economic and political tactic, France has been attempting for several years to have the European Union (EU) adopt legislation forbidding the cultivation of industrial hemp cultivars with more than 0.1% THC, which would mean that primarily French varieties would have to be cultivated in Europe. However, the Canadian government has found that some French material has proven to be excessively high in THC.
^ Parliament of the Czech Republic (1998), Explanatory Report to Act No. 112/1998 Coll., which amends the Act No. 140/1961 Coll., the Criminal Code, and the Act No. 200/1990 Coll., on misdemeanors (in Czech), Prague "Podle čl. 36 Jednotné úmluvy o omamných látkách ze dne 31. března 1961 (č. 47/1965 Sb.) se signatáři zavazují k trestnímu postihu tam uvedených forem nakládání s drogami včetně jejich držby. Návrh upouští od dosavadní beztrestnosti držby omamných a psychotropních látek a jedů pro svoji potřebu. Dosavadní beztrestnost totiž eliminuje v řadě případů možnost postihu dealerů a distributorů drog."
• Speaking of which: Has it been third-party tested? Nearly every expert Health spoke to agreed that your CBD products should be tested by a third party to confirm the label's accuracy. This is a real concern in the industry—take the 2017 Journal of the American Medical Association study, for example, which tested 84 CBD products and found that 26% contained lower doses than stated on the bottle. Look for a quality assurance stamp or certificate of analysis from a third party (aka not the actual brand) or check the retailer's website if you don't see it on the product's label.
Hi, Congrats on finishing chemo & radiation that’s awesome!! I wish you the best of luck!! I was actually wanting to know about dosage for cancer as well..My parents both have recently been diagnosed with cancer 4 months apart and are currently going thru chemo together. I have tried looking for the dosage info but can never find what i’m looking for..I want to try to help lesson the chemo side effects and hopefully kill some of the cancer cells. Can someone please help us?Thank You Christy
At an epidemiological level, a dose–response relationship exists between cannabis use and increased risk of psychosis and earlier onset of psychosis. Although the epidemiological association is robust, evidence to prove a causal relationship is lacking. But a biological causal pathway is plausible, especially if there is a genetic predisposition to mental illness, in which case cannabis may be a trigger.[better source needed]
Hemp plants are almost always cultivated outdoors, as opposed to marijuana plants, which are mostly planted in greenhouse or indoor settings. Because hemp is susceptible to the same predators diseases and insects that attack marijuana, the hemp industry employs a technique called crop rotation, in which alternating crops are planted in the same place, to avoid any buildup of these organisms and allow nutrients to return to the soil. The specific order of crop rotation and types of crops being rotated with hemp will depend on the location of the farm. Hemp is also used as a rotational crop at farms where it is not the primary agricultural product.
In 1988, the first cannabinoid receptor was identified (CB1) (Howlett et al 1988) and in 1993, a second was described (CB2) (Munro et al 1993). Both are 7-domain G-protein coupled receptors affecting cyclic-AMP, but CB1 is more pervasive throughout the body, with particular predilection to nociceptive areas of the central nervous system and spinal cord (Herkenham et al 1990; Hohmann et al 1999), as well as the peripheral nervous system (Fox et al 2001; Dogrul et al 2003) wherein synergy of activity between peripheral and central cannabinoid receptor function has been demonstrated (Dogrul et al 2003). CB2, while commonly reported as confined to lymphoid and immune tissues, is also proving to be an important mediator for suppressing both pain and inflammatory processes (Mackie 2006). Following the description of cannabinoid receptors, endogenous ligands for these were discovered: anandamide (arachidonylethanolamide, AEA) in 1992 in porcine brain (Devane et al 1992), and 2-arachidonylglycerol (2-AG) in 1995 in canine gut tissue (Mechoulam et al 1995) (Figure 1). These endocannabinoids both act as retrograde messengers on G-protein coupled receptors, are synthesized on demand, and are especially active on glutamatergic and GABA-ergic synapses. Together, the cannabinoid receptors, their endogenous ligands (“endocannabinoids”) and metabolizing enzymes comprise the endocannabinoid system (ECS) (Di Marzo et al 1998), whose functions have been prosaically termed to be “relax, eat, sleep, forget and protect” (p. 528). The endocannabinoid system parallels and interacts at many points with the other major endogenous pain control systems: endorphin/enkephalin, vanilloid/transient receptor potential (TRPV), and inflammatory. Interestingly, our first knowledge of each pain system has derived from investigation of natural origin analgesic plants, respectively: cannabis (Cannabis sativa, C. indica) (THC, CBD and others), opium poppy (Papaver somniferun) (morphine, codeine), chile peppers (eg, Capsicum annuum, C. frutescens, C. chinense) (capsaicin) and willow bark (Salix spp.) (salicylic acid, leading to acetylsalicylic acid, or aspirin). Interestingly, THC along with AEA and 2-AG, are all partial agonists at the CB1 receptor. Notably, no endocannabinoid has ever been administered to humans, possibly due to issues of patentability and lack of commercial feasibility (Raphael Mechoulam, pers comm 2007). For an excellent comprehensive review of the endocannabinoid system, see Pacher et al (2006), while Walker and Huang have provided a key review of antinociceptive effects of cannabinoids in models of acute and persistent pain (Walker and Huang 2002).
Overall, researchers agree that while there isn’t conclusive data to support CBD oil as the preferred method of pain management, these types of products have a lot of potential. CBD products might be able to offer relief for many people who have chronic pain, all without causing intoxication and dependence. Oil versions of CBD may not be as effective as other forms, and more human studies are needed.
The use of Cannabis for seed oil (Fig. 36) began at least 3 millennia ago. Hempseed oil is a drying oil, formerly used in paints and varnishes and in the manufacture of soap. Present cultivation of oilseed hemp is not competitive with linseed for production of oil for manufacturing, or to sunflower and canola for edible vegetable oil. However, as noted below, there are remarkable dietary advantages to hempseed oil, which accordingly has good potential for penetrating the salad oil market, and for use in a very wide variety of food products. There is also good potential for hemp oil in cosmetics and skin-care products.
Researchers in New Zealand have studied whether cannabis can be used to treat severe motor and vocal tics in those suffering from Tourette syndrome. The study concluded that subjects who took a controlled THC-CBD medicated spray showed marked improvement in the frequency and severity of motor and vocal tics post-treatment. Although the study is only a small clinical trial, it is one of the first to specifically analyze the effects of cannabis on Tourette syndrome.
Cannabidiol, or CBD for short, is a natural phyto-cannabinoid (or plant-based chemical compound) found in cannabis plants, including hemp and marijuana. Unlike other cannabinoids — namely tetrahydrocannabinol, or THC — CBD does not produce any psychoactive effects, and will actually counteract these effects to a degree. CBD will induce feelings of sleepiness; for this reason, it can be an effective soporific for people who struggle to fall and/or remain asleep due to insomnia and other sleep disorders.